Vutrisiran nell’ATTR-CM: impatto sulla prognosi e benefici pratici per i pazienti

The approval of RNA silencers for patients with transthyretin cardiac amyloidosis (ATTR-CM) marks a significant step forward in the management of the disease. According to Alberto Cipriani (University of Padua), the results of the HELIOS-B study in particular have shown that vutrisiran is associated with a reduction in the risk of all-cause mortality and hospitalization for heart failure, as well as a slowing of functional decline and quality of life. This benefit was also observed in a contemporary patient population, many of whom were already receiving treatment with a transthyretin stabilizer. In addition to clinical efficacy, the therapy also offers practical advantages for patients and caregivers. With the publication in the Official Journal and the reimbursement of vutrisiran for ATTR-CM, patients have access to a disease-modifying therapy administered subcutaneously every three months, potentially for self-administration. This approach reduces therapeutic burden and visits to healthcare facilities, promoting independence and improving adherence and quality of life. Questions 0:00 Introduction 0:11 How is RNA silencing changing the treatment landscape in cardiology in light of the approval of vutrisiran for ATTR-CM? 2:48 What benefits does the availability of a three-monthly subcutaneous vutrisiran therapy offer patients and caregivers? Follow Cardioinfo: Website: https://bit.ly/3fzgryk X: https://bit.ly/2AGPpqj Linkedin: https://bit.ly/2UVRCET